Sonia Tabacova
US Food and Drug Administration
Rockville
Maryland 20852
USA
Name/email consistency: high
- Mode of action: angiotensin-converting enzyme inhibition--developmental effects associated with exposure to ACE inhibitors. Tabacova, S. Crit. Rev. Toxicol. (2005)
- Atenolol developmental toxicity: animal-to-human comparisons. Tabacova, S., Kimmel, C.A., Wall, K., Hansen, D. Birth Defects Res. Part A Clin. Mol. Teratol. (2003)
- Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Tabacova, S., Little, R., Tsong, Y., Vega, A., Kimmel, C.A. Pharmacoepidemiol. Drug. Saf (2003)